Top Page
AstraZeneca (AZN) vs. S&P 500 (SPY)
AstraZeneca Business Overview & Revenue Model
AstraZeneca Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 54.07B | 45.81B | 44.35B | 37.42B | 26.62B | Gross Profit |
| 43.87B | 37.77B | 31.96B | 24.98B | 21.32B | EBIT |
| 10.00B | 8.19B | 3.76B | 1.06B | 5.16B | EBITDA |
| 17.12B | 13.91B | 9.09B | 5.11B | 8.08B | Net Income Common Stockholders |
| 7.04B | 5.96B | 3.29B | 112.00M | 3.20B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 5.65B | 5.86B | 6.41B | 6.40B | 7.99B | Total Assets |
| 104.03B | 101.12B | 96.48B | 105.36B | 66.73B | Total Debt |
| 30.11B | 28.62B | 29.23B | 30.78B | 20.38B | Net Debt |
| 24.63B | 22.78B | 23.07B | 24.45B | 12.55B | Total Liabilities |
| 63.16B | 61.95B | 59.42B | 66.08B | 51.09B | Stockholders Equity |
| 40.79B | 39.14B | 37.04B | 39.27B | 15.62B |
| Cash Flow | Free Cash Flow | |||
| 7.28B | 6.57B | 7.24B | 3.76B | 2.19B | Operating Cash Flow |
| 11.86B | 10.35B | 9.81B | 5.96B | 4.80B | Investing Cash Flow |
| -7.98B | -4.06B | -2.96B | -11.06B | -285.00M | Financing Cash Flow |
| -4.00B | -6.57B | -6.82B | 3.65B | -2.20B |
AstraZeneca Technical Analysis
AstraZeneca Peers Comparison
AstraZeneca Earnings Call Summary
AstraZeneca Corporate Events
AstraZeneca PLC announced that as of 28 February 2025, its issued share capital with voting rights consists of 1,550,607,175 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, impacting how they manage their interests in the company.
AstraZeneca’s Imfinzi, in combination with chemotherapy, has been recommended for approval by the CHMP in the EU for treating adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. This recommendation is based on the AEGEAN Phase III trial results, which demonstrated a 32% reduction in the risk of recurrence, progression, or death compared to neoadjuvant chemotherapy alone. The approval could significantly enhance AstraZeneca’s position in the oncology market, providing a new treatment option for patients with early-stage lung cancer, addressing a high unmet medical need.
AstraZeneca, in collaboration with Daiichi Sankyo, announced that their drug Enhertu has been recommended for approval in the EU for treating patients with HER2-low or HER2-ultralow metastatic breast cancer, based on the DESTINY-Breast06 Phase III trial results. This recommendation by the Committee for Medicinal Products for Human Use (CHMP) marks a significant advancement in breast cancer treatment, offering a new HER2-directed therapy option for patients who have progressed on endocrine therapy, potentially improving outcomes and shifting current treatment paradigms.
AstraZeneca announced positive interim results from the SERENA-6 Phase III trial, where its drug camizestrant, combined with CDK4/6 inhibitors, showed significant improvement in progression-free survival for patients with HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. This marks the first time a next-generation oral SERD has demonstrated such benefits in the first-line setting, potentially shifting clinical practice and offering a new standard-of-care for these patients. The trial’s design, using ctDNA to guide treatment switches, highlights a novel approach in managing endocrine resistance, with implications for future breast cancer therapies.
AstraZeneca announced the filing of its 2024 Annual Report on Form 20-F with the US Securities and Exchange Commission, providing stakeholders access to its complete audited financial statements. This filing underscores AstraZeneca’s transparency and commitment to compliance, which can enhance trust among investors and affirm its strong position in the biopharmaceutical industry.
The Capital Group Companies, Inc., a major investment management company based in Los Angeles, has acquired a significant stake in AstraZeneca PLC, crossing a 5% threshold of voting rights on January 29, 2025. This acquisition highlights Capital Group’s strategic interest in AstraZeneca’s operations, potentially influencing the company’s future governance and strategic decisions.
AstraZeneca PLC has published its Annual Report and Form 20-F Information for 2024, which is available on the company’s website and will soon be accessible via the National Storage Mechanism. The report includes key regulated information such as principal risks, directors’ responsibilities, and related party transactions. The company’s Annual General Meeting is scheduled for April 11, 2025. This announcement highlights AstraZeneca’s commitment to transparency and regulatory compliance, potentially influencing its stakeholders and market positioning.
AstraZeneca announced proposed board changes with Karen Knudsen, a recognized cancer scientist, being nominated as a Non-Executive Director at the upcoming AGM in April 2025. Knudsen, known for her work in oncology and healthcare innovation, is set to join the Science and Sustainability Committees. Concurrently, Deborah DiSanzo and Andreas Rummelt will retire from the board. These changes reflect AstraZeneca’s strategic focus on enhancing its expertise in science and sustainability, potentially influencing its industry positioning and operations.
AstraZeneca reported a robust financial performance for the year 2024, with Total Revenue increasing by 21% and Core EPS growing by 19%. The growth was primarily driven by strong sales across its key therapeutic areas, including a 24% rise in oncology. The company also achieved milestones in drug approvals in various regions and announced plans to increase dividends and capital expenditure in 2025. Furthermore, AstraZeneca is facing a legal issue in China regarding unpaid importation taxes, which it is cooperating with authorities to resolve.
AstraZeneca PLC announced that as of 31 January 2025, its issued share capital with voting rights comprises 1,550,581,134 ordinary shares. This figure is crucial for shareholders to determine their notification requirements under the UK’s Financial Conduct Authority’s Disclosure and Transparency Rules, indicating transparency in the company’s voting rights structure and facilitating shareholder engagement.
AstraZeneca’s Imfinzi has been recommended for approval in the European Union as the first immunotherapy for limited-stage small cell lung cancer (LS-SCLC) based on the ADRIATIC Phase III trial, which demonstrated a significant survival benefit. This recommendation is expected to enhance AstraZeneca’s position in the oncology market by providing a new treatment option for LS-SCLC patients, potentially improving survival rates and offering a practice-changing therapy in Europe.
AstraZeneca and Daiichi Sankyo’s Enhertu has received FDA approval in the US for treating patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after disease progression on endocrine therapies. This approval, based on the DESTINY-Breast06 Phase III trial results, marks a significant advancement by allowing a new treatment option that offers a median progression-free survival of over a year, positioning Enhertu as a potential new standard of care and broadening the patient population eligible for HER2-directed therapies.
AstraZeneca, in collaboration with Daiichi Sankyo, has received its first US approval for Datroway (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate, for treating previously treated metastatic HR-positive, HER2-negative breast cancer. The approval, based on the TROPION-Breast01 Phase III trial results, marks a significant milestone in offering a new treatment option, reducing disease progression or death risk by 37% compared to chemotherapy, thereby advancing AstraZeneca’s goal to provide innovative cancer therapies.
AstraZeneca announced the US FDA approval of Calquence in combination with bendamustine and rituximab for previously untreated mantle cell lymphoma (MCL) patients, marking the first BTK inhibitor approved for first-line MCL treatment. This approval, based on ECHO Phase III trial results, enhances AstraZeneca’s position in oncology by offering a new treatment option for a rare and aggressive cancer, thus potentially transforming MCL patient care and reinforcing Calquence as a key therapy in blood cancers.
AstraZeneca has announced its issued share capital with voting rights as of December 31, 2024, stands at 1,550,546,239 ordinary shares. This figure is crucial for shareholders to calculate and notify any changes in their interest in AstraZeneca under the UK’s financial regulations. This transparency in voting rights and capital structure is vital for maintaining compliance with the UK Financial Conduct Authority’s rules, potentially impacting investor relations and market trust.
AstraZeneca and Daiichi Sankyo have withdrawn their EU marketing application for datopotamab deruxtecan for advanced nonsquamous non-small cell lung cancer following feedback from the European Medicines Agency. Despite this, they remain committed to advancing this treatment through ongoing clinical trials and are continuing to pursue its potential in various lung cancer settings. The withdrawal highlights the challenges in bringing new cancer therapies to market and underscores the companies’ resilience in exploring further development opportunities for this investigational drug.
AstraZeneca’s Tagrisso has been approved in the EU for treating adult patients with unresectable EGFR-mutated non-small cell lung cancer (NSCLC), marking a significant breakthrough as the first and only EGFR inhibitor for this condition in the region. The approval, based on the LAURA Phase III trial results, shows Tagrisso significantly extends progression-free survival, setting a new standard of care for these patients and reinforcing the importance of timely EGFR mutation testing.
AstraZeneca PLC announced the appointment of Rene Haas and Birgit Conix as Non-Executive Directors, effective from January and February 2025, respectively. Rene Haas, currently CEO of Arm, brings extensive experience in technology and AI, while Birgit Conix, CFO of Sonova, brings significant financial and pharmaceutical industry experience. These appointments are part of AstraZeneca’s strategic board refreshment plan as four current directors near their tenure limits, potentially strengthening the company’s governance and industry positioning.
AstraZeneca’s Imfinzi has received FDA approval as the first immunotherapy for limited-stage small cell lung cancer, showcasing a significant advance in treatment with a 27% reduction in mortality risk. The approval is based on the ADRIATIC Phase III trial results, marking a breakthrough in a disease known for its rapid progression and poor prognosis. This development underscores AstraZeneca’s commitment to improving survival rates and offering new hope to patients.